News by subject: TRI

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announces it will be exhibiting at the American Association for Cancer Research (AACR)...

Bio-Techne Corporation today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR),...

Filament Health Corp. (NEO: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET....

TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (ClinicalTrials.gov:...

SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug...

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its innovative BLyS/APRIL...

Vanda Pharmaceuticals Inc. (Vanda) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I...

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a...

ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview...

Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment. One trial focuses on molecular imaging and the other on molecular therapy; both are poised to redefine the standard of care for...

EpicentRx, Inc, a clinical-stage biotechnology drug and device company with two therapeutic platforms that address cancer and inflammatory diseases of unmet clinical need, today announced that an abstract on its lead therapy, AdAPT-001, will be...

GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug...

Lucius Partners, LLC ("LP") today announced that its portfolio company, AerWave Medical, Inc., has received an allowance from the Georgian Ministry of Health to initiate its first in human studies of the Company's unique ultrasound technique for...

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 6, 2024, the European...

City of Hope, one of the largest cancer research and treatment organizations in the United States, and DELFI...

? Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia ? ? PREEMPT CRC, the largest study of a blood-based test for CRC, enrolled 48,995 participants,...

Voiant, a leader in clinical trial imaging solutions, is proud to announce the successful completion of an inspection conducted by the U.S. Food and Drug Administration (FDA). The rigorous inspection encompassed an evaluation of the company's...

LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its...

The Neurology Department of China Medical University Hospital (CMUH, Taiwan), teaming up with AI Center at CMUH, has established the AISIA (Artificial Intelligence for Stroke Image Analysis) platform, which contains the "NCCT-based Ischemic Stroke...

Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of...

Myrtelle Inc., ("Myrtelle" or the "Company"), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative...

MIRA Pharmaceuticals, Inc.  ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today shares updates on the ongoing pre-clinical studies of its investigational...

YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the...

Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has launched an all-in-one package of contract research organization (CRO) services specifically designed for clinical research into...

Jazz Pharmaceuticals plc  today announced that the company has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug...

NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT)....

Peerbridge Health, developer of a hospital-grade, remote diagnostic platform that harnesses AI to detect early signs of heart failure, today announced results of a recent feasibility trial showing its technology had a nearly 96% accuracy rate in...

Labcorp , a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research®...

On the pre-specified primary efficacy endpoint of Treatment Failure at week 24, 29% of subjects receiving brepocitinib 45 mg and 44% of subjects receiving brepocitinib 15 mg met Treatment Failure criteria (lower failure rates reflect greater...

Concept Medical has been granted 'IDE Approval' from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, to initiate a clinical study for the treatment of stenotic lesions of Arteriovenous...

Tethis S.p.A., a pioneer in the development of an innovative platform for liquid biopsy testing, is pleased to announce the enrollment of the first two patients in the clinical study TET-22-001. This study, titled "Feasibility evaluation of See.d...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology...

Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that preclinical data for ADRX-0706 will be presented at the...

Azenta, Inc. today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes...

The field of psychiatry may have a new ally in the form of a medical ketogenic diet, according to the findings of a pioneering pilot study published in Psychiatry Research and announced today by Stanford Medicine. The study, supported by funding from...

Biolexis Therapeutics, Inc. a clinical-stage biopharmaceutical company with a novel AI-assisted drug discovery platform technology, today announced it will present five posters at the 2024 American Association for Cancer Research (AACR), taking place...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and...

In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk ? a critical characterization step in the candidate...

Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:...

Cellenkos®, a clinical stage biotech cell therapy company focused on treating autoimmune diseases and inflammatory disorders, today announced that it has entered into a sponsored research agreement with the Icahn School of Medicine at Mount Sinai,...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee...

Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and...

BioArctic AB's (publ) (Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi®) intravenous (IV) maintenance dosing to the...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S....

Li Ou, Ph.D., Vice President of Research at Avirmax Inc., will chair two scientific sessions at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. ASGCT is the largest...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage...